Drew Holzapfel brings a deep foundation in healthcare strategy to High Lantern Group and itsclients. Over the course of his career, Drew has held positions in the federal government and with pharmaceutical companies, device manufacturers, and consulting firms, including Pfizer, The White House, and US Department of Health and Human Services. As a partner at High Lantern Group, he has led the firm’s work with top biopharmaceutical companies to drive market readiness, position key policy issues, build partnerships and gain third-party organization support. He also has helped many nonprofit organizations and coalitions develop their positioning strategies and strengthen their influence and impact.
Drew has unique expertise in Alzheimer’s disease, mental health, and neuroscience and has been recognized for his work with policymakers, advocacy organizations, corporations, international organizations, and governments. He is a Founding Board Member of The Global Alzheimer’s Platform Foundation, the Executive Director of The Global CEO Initiative on Alzheimer’s Disease, Founding Board Member of Commit2Kind, a non-profit focused on anti-bullying, and served as Acting President and Board Member of UsAgainstAlzheimer’s. Drew earned his Bachelor’s degree from Emory University and a Master’s of Business Administration from The University of Maryland.